Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective study
Maintenance bevacizumab was associated with significantly prolonged PFS and OS in patients with advanced or recurrent cervical cancer who tolerated bevacizumab, but toxicity may preclude the use of maintenance therapy.
Authors
- Peter G. Rose (ORCID: https://orcid.org/0000-0003-2676-0166)
- Melissa Yurch
- Michelle Kuznicki (ORCID: https://orcid.org/0000-0002-7954-1373)
- Johanna Kelley (ORCID: https://orcid.org/0000-0002-1287-7817)
- Sabrina Bedell (ORCID: https://orcid.org/0000-0003-0267-2209)
- Meng Yao (ORCID: https://orcid.org/0000-0003-3341-6830)
- Danielle Chau
Institutions
- Cleveland Clinic (US)
- University of Utah Hospital (US)
- Virginia Gastroenterology Institute (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1016/j.gore.2025.101706
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.06